Invezz
09 Jul 2026, 08:49 UTC · 1h ago
AstraZeneca shares plunge as Wainua fails late-stage heart disease trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Invezz
09 Jul 2026, 08:49 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
AstraZeneca's drug Wainua failed to meet its primary objective in a late-stage clinical trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). — The failure of a closely watched, late-stage asset removes a multi-billion-dollar growth driver and directly caused a ~10% drop in share price.
-0.80The failure of Wainua may lead investors to reprice other remaining late-stage readouts, such as SERENA-4 and AVANZAR, with a higher probability of disappointment. — A failure in one major program can create a contagion effect, lowering confidence in the broader pipeline efficacy.
-0.50Ionis Pharmaceuticals retains the core antisense platform and other pipeline assets despite the Wainua setback. — The underlying technology platform remains intact, suggesting the market may be overreacting to a single-program failure for Ionis.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
Shares plunged nearly 10% following the failure of a late-stage clinical trial for Wainua.
The drug failure is a setback for a partnership program, though the author argues the market may be over-discounting the broader platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors - Finance
2h ago
